RNA Therapeutic for ADOA | Eye Disease

PYC Therapeutics

This video provides an overview of autosomal dominant optic atrophy (ADOA) and the mechanism of action (MoA) of PYC’s mRNA therapeutic candidate, PYC-001.

Previous
Previous

RNA Therapeutic for ADKPD / Kidney Disease / MoA / PYC Therapeutics

Next
Next

RNA Therapeutic for Phelan-McDermid Syndrome / MoA / PYC Therapeutics